Literature DB >> 7107367

The enhanced sensitivity of mammalian cells to killing by X rays after prolonged exposure to several nitroimidazoles.

E J Hall, M Astor, J Biaglow, J C Parham.   

Abstract

Electron affinic compounds, such as misonidazole, preferentially sensitize hypoxic cells to killing by X rays, and are also preferentially cytotoxic to cells deficient in oxygen. Prolonged exposure of cells to misonidazole prior to irradiation results in an increased radiosensitization. This is expressed as the Extra Enhancement Ratio (EER), defined as the ratio of the doses delivered immediately after the addition of the sensitizer or after prolonged incubation, that produce a given biological effect. Chinese hamster V79 cells have been used to investigate this prolonged incubation effect for a variety of 2-nitroimidazoles including misonidazole, desmethylmisonidazole and SR-2508 and as well as two ortho-substituted-4-nitroimidazoles with a bromine or sulfonamide group substituted in the 5-position. A considerable variation was observed in the magnitude of the Extra Enhancement Ratio (EER) produced by pre-incubation with different compounds at concentrations that produce the same sensitizing effect. There is a good correlation between the EER and the measured rate at which the various sensitizers deplete cells of non-protein sulfhydryl compounds. There is also a good correlation between the EER and the fraction of cells killed by the pre-incubation period in the drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107367     DOI: 10.1016/0360-3016(82)90658-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.

Authors:  Peter Wardman
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

Review 2.  Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

Authors:  Amanda J Walker; Sara R Alcorn; Amol K Narang; Katriana M Nugent; Aaron T Wild; Joseph M Herman; Phuoc T Tran
Journal:  Curr Probl Cancer       Date:  2013-10-05       Impact factor: 3.187

3.  Optimizing the interval between administration of misonidazole and irradiation: an in vitro study.

Authors:  E J Hall; M Astor
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

Review 4.  Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.

Authors:  K J Harrington; L J Billingham; T B Brunner; N G Burnet; C S Chan; P Hoskin; R I Mackay; T S Maughan; J Macdougall; W G McKenna; C M Nutting; A Oliver; R Plummer; I J Stratford; T Illidge
Journal:  Br J Cancer       Date:  2011-07-19       Impact factor: 7.640

Review 5.  Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.

Authors:  Sara Alcorn; Amanda J Walker; Nishant Gandhi; Amol Narang; Aaron T Wild; Russell K Hales; Joseph M Herman; Danny Y Song; Theodore L Deweese; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.